- Trial phase
- EUA (Emergency Use Authorization) / Marketed
- Time to market
- Already on the market under EUA since December 2021. Must obtain full FDA approval by June 29, 2027 or lose U.S. marketing authorization.
- Why 4/10
- LAGEVRIO is an EUA-authorized drug with no pending PDUFA date or pivotal readout. The next hard catalyst is the June 29, 2027 EUA termination deadline (~8 months away), but the drug represents less than 1% of Merck's $66B+ annual revenue, so even a binary regulatory outcome would not materially move MRK shares.
The next hard catalyst for LAGEVRIO is the June 29, 2027 deadline when the COVID-19 EUA declaration terminates. Merck must obtain full FDA approval (an NDA) by that date or lose the ability to market LAGEVRIO in the U.S. However, with sales already collapsing to $138M in Q3 2026 (down 64% YoY) and the drug representing a trivial fraction of Merck's $66B+ annual revenue, this binary regulatory event is unlikely to move MRK shares materially. Watch for any Merck announcement of an NDA submission for molnupiravir, which would signal intent to pursue full approval before the deadline.
Price Chart
Executive Summary
LAGEVRIO (molnupiravir) is Merck's oral antiviral COVID-19 treatment, authorized under FDA Emergency Use Authorization (EUA) since December 2021. It has never received full FDA approval. On June 30, 2026, HHS announced the COVID-19 EUA declaration will terminate on June 29, 2027, meaning LAGEVRIO must obtain full NDA approval by that date or lose U.S. market access. Meanwhile, sales are in steep decline: Q3 2026 revenue was $138M (down 64% YoY), and the drug faces strong competition from Pfizer's fully-approved Paxlovid. For Merck, a $346B market cap company with $66B+ in annual revenue driven by Keytruda, Gardasil, and Winrevair, LAGEVRIO is a negligible contributor (less than 1% of sales) and its decline does not materially affect the investment thesis.
How It Works
Molnupiravir is an oral antiviral pill that works by causing the virus to make many copying errors when it tries to replicate, essentially forcing the virus to mutate itself to death. It is taken by mouth as capsules and is designed for early treatment of mild-to-moderate COVID-19 in high-risk adults.
Trial Status
LAGEVRIO is commercially available under FDA EUA. The Phase 3 MOVe-AHEAD trial evaluating it for post-exposure prophylaxis failed to show a statistically significant reduction in COVID-19 risk. No new pivotal trials are actively recruiting. The key regulatory overhang is the June 29, 2027 EUA termination deadline.
The Two-Sided Case
Upcoming Catalysts
- June 29, 2027: Deadline for COVID-19 drug EUA termination. Merck must obtain full FDA approval (NDA) by this date or LAGEVRIO loses U.S. market access.
- Any announcement of an NDA submission for molnupiravir would signal intent to pursue full approval before the EUA deadline.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report